Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17874217 | 1.00 | NOTUM (0.35) | NOTUMHSD11B1L3MBTL1CNR2 | |
| SCHEMBL17874204 | 1.00 | NOTUM (0.35) | NOTUMHSD11B1L3MBTL1CNR2 | |
| SCHEMBL17887750 | 0.78 | POLB (0.40) | NOTUMHSD11B1L3MBTL1CNR2 | |
| SCHEMBL17374194 | 0.69 | HCRTR1 (0.30) | — | |
| SCHEMBL1118416 | 0.68 | LDHA (0.45) | HSD11B1L3MBTL1 | |
| SCHEMBL17374384 | 0.68 | SMYD3 (0.37) | NOTUM | |
| SCHEMBL17874284 | 0.68 | SMYD3 (0.37) | NOTUM | |
| SCHEMBL17874205 | 0.68 | SMYD3 (0.37) | NOTUM | |
| SCHEMBL17926692 | 0.67 | NPC1 (0.30) | — | |
| SCHEMBL440391 | 0.66 | L3MBTL1 (0.43) | NOTUMHSD11B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344023-B2 | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10344023-B2 | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-10174014-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170362214-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362214-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362214-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-17 | — | — | US | disclosed |
| WO-2016105468-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105468-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344023-B2 | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis | CFTR, ABCC5, ABCD3 | NOTUM 1559/4885HSD11B1 3928/4885L3MBTL1 1740/4885 |
| US-20170362214-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | CFTR, ABCC5, ABCD3 | NOTUM 1559/4885HSD11B1 3928/4885L3MBTL1 1740/4885 |
| US-10174014-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, ABCB4, SCNN1B | NOTUM 955/4885HSD11B1 3907/4885L3MBTL1 3551/4885 |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | NOTUM 955/4885HSD11B1 3907/4885L3MBTL1 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.